CADTH has received the notice of a pending submission from Novartis for secukinumab for patients with moderate to severe plaque psoriasis.  For information about the patient input process or for additional instructions, please see the Patient Input page of the CADTH website. Note that only patient groups may submit input.

For more details, go to: http://www.cadth.ca/en/products/cdr/patient-group-input-form/390